World's Best Scientists 2026 revealed!
Thomas P. Monath

Thomas P. Monath

D-Index & Metrics

Immunology

D-Index
92
Citations
23536
World Ranking
1014
National Ranking
549

Medicine

D-Index
94
Citations
25278
World Ranking
10624
National Ranking
5460

Thomas P. Monath publication distribution in Immunology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Immunology in 2026. The highlighted bar marks where Thomas P. Monath sits on this spectrum.

62–71 publications: 9 scientists 72–81 publications: 23 scientists 82–91 publications: 40 scientists 92–101 publications: 72 scientists 102–111 publications: 86 scientists 112–121 publications: 108 scientists 122–131 publications: 150 scientists 132–141 publications: 160 scientists 142–151 publications: 159 scientists 152–161 publications: 189 scientists 162–171 publications: 166 scientists 172–181 publications: 181 scientists 182–191 publications: 188 scientists 192–201 publications: 187 scientists 202–211 publications: 178 scientists 212–221 publications: 158 scientists 222–231 publications: 168 scientists 232–241 publications: 159 scientists 242–251 publications: 160 scientists 252–261 publications: 148 scientists 262–271 publications: 116 scientists 272–281 publications: 125 scientists 282–291 publications: 115 scientists 292–301 publications: 111 scientists 302–311 publications: 95 scientists 312–321 publications: 97 scientists 322–331 publications: 97 scientists 332–341 publications: 99 scientists 342–351 publications: 96 scientists 352–361 publications: 68 scientists 362–371 publications: 76 scientists 372–381 publications: 71 scientists 382–391 publications: 71 scientists 392–401 publications: 62 scientists 402–411 publications: 54 scientists 412–421 publications: 41 scientists 422–431 publications: 63 scientists 432–441 publications: 53 scientists 442–451 publications: 31 scientists 452–461 publications: 42 scientists 462–471 publications: 40 scientists 472–481 publications: 29 scientists 482–491 publications: 34 scientists 492–501 publications: 30 scientists 502–511 publications: 23 scientists 512–521 publications: 41 scientists 522–531 publications: 29 scientists 532–541 publications: 28 scientists 542–551 publications: 16 scientists 552–561 publications: 18 scientists 562–571 publications: 18 scientists 572–581 publications: 17 scientists 582–591 publications: 17 scientists 592–601 publications: 17 scientists 602–611 publications: 19 scientists 612–621 publications: 13 scientists 622–631 publications: 12 scientists 632–641 publications: 11 scientists 642–651 publications: 16 scientists 652–661 publications: 9 scientists 662–671 publications: 5 scientists 672–681 publications: 13 scientists 682–691 publications: 12 scientists 692–701 publications: 6 scientists 702–711 publications: 6 scientists 712–721 publications: 9 scientists 722–731 publications: 9 scientists 732–741 publications: 6 scientists 742–751 publications: 11 scientists 752–761 publications: 10 scientists 762–771 publications: 7 scientists 772–781 publications: 12 scientists 782–791 publications: 7 scientists 792–801 publications: 5 scientists 802–806 publications: 1 scientists 807+ publications: 100 scientists
62 publications 807+

This scientist: 250 publications — 51st percentile

51% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 807 publications or more.

Thomas P. Monath D-index placement in Immunology in 2026

The chart shows the D-index (discipline H-index) distribution of Immunology scientists ranked by Research.com in 2026. The highlighted bar marks where Thomas P. Monath sits on this spectrum.

40–41 D-Index: 28 scientists 42–43 D-Index: 91 scientists 44–45 D-Index: 157 scientists 46–47 D-Index: 192 scientists 48–49 D-Index: 175 scientists 50–51 D-Index: 188 scientists 52–53 D-Index: 177 scientists 54–55 D-Index: 155 scientists 56–57 D-Index: 194 scientists 58–59 D-Index: 201 scientists 60–61 D-Index: 197 scientists 62–63 D-Index: 201 scientists 64–65 D-Index: 173 scientists 66–67 D-Index: 167 scientists 68–69 D-Index: 172 scientists 70–71 D-Index: 199 scientists 72–73 D-Index: 184 scientists 74–75 D-Index: 133 scientists 76–77 D-Index: 162 scientists 78–79 D-Index: 127 scientists 80–81 D-Index: 121 scientists 82–83 D-Index: 125 scientists 84–85 D-Index: 121 scientists 86–87 D-Index: 102 scientists 88–89 D-Index: 96 scientists 90–91 D-Index: 75 scientists 92–93 D-Index: 72 scientists 94–95 D-Index: 74 scientists 96–97 D-Index: 66 scientists 98–99 D-Index: 68 scientists 100–101 D-Index: 49 scientists 102–103 D-Index: 60 scientists 104–105 D-Index: 54 scientists 106–107 D-Index: 36 scientists 108–109 D-Index: 23 scientists 110–111 D-Index: 52 scientists 112–113 D-Index: 41 scientists 114–115 D-Index: 34 scientists 116–117 D-Index: 25 scientists 118–119 D-Index: 28 scientists 120–121 D-Index: 11 scientists 122–123 D-Index: 20 scientists 124–125 D-Index: 27 scientists 126–127 D-Index: 19 scientists 128–129 D-Index: 20 scientists 130–131 D-Index: 16 scientists 132–133 D-Index: 17 scientists 134–135 D-Index: 14 scientists 136–137 D-Index: 15 scientists 138–139 D-Index: 9 scientists 140–141 D-Index: 11 scientists 142–143 D-Index: 9 scientists 144–145 D-Index: 9 scientists 146–147 D-Index: 7 scientists 148–149 D-Index: 7 scientists 150–151 D-Index: 7 scientists 152–153 D-Index: 5 scientists 154–155 D-Index: 8 scientists 156 D-Index: 6 scientists 157+ D-Index: 96 scientists
40 D-Index 157+

This scientist: 92 D-Index — 80th percentile

80% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 157 D-Index or more.

Research.com Recognitions

  • 2011 - Fellow of the American Society of Tropical Medicine and Hygiene (ASTMH)

Overview

Thomas P. Monath is affiliated with Crozet BioPharma in the United States and has contributed extensively to research in the field of medicine, with a focus on infectious diseases. Their work spans multiple specialized areas including infectious diseases, public health, epidemiology, molecular biology, and immunology.

Their research topics cover a range of subjects related to viral infections and outbreaks, with particular attention to viral infections and vectors, mosquito-borne diseases, SARS-CoV-2 and COVID-19 research, virology and viral diseases, and COVID-19 epidemiological and clinical research studies.

Among notable publication venues, Monath has frequently published in:

  • Vaccine
  • American Journal of Tropical Medicine and Hygiene
  • npj Vaccines
  • Viruses
  • The Journal of Infectious Diseases

Their collaboration network includes frequent coauthors such as:

  • Claire-Anne Siegrist
  • Peter G. Kremsner
  • Donata Medaglini
  • Tom H. M. Ottenhoff
  • Francesco Santoro

Monath's recent papers reflect their research interests and include:

  • "The Origin of COVID-19 and Why It Matters," 2020, American Journal of Tropical Medicine and Hygiene
  • "Immunogenicity and safety of fractional doses of yellow fever vaccines: a randomised, double-blind, non-inferiority trial," 2021, The Lancet
  • "A Randomized Dose-Escalating Phase I Trial of a Replication-Deficient Lymphocytic Choriomeningitis Virus Vector-Based Vaccine Against Human Cytomegalovirus," 2020, The Journal of Infectious Diseases
  • "A novel RBD-protein/peptide vaccine elicits broadly neutralizing antibodies and protects mice and macaques against SARS-CoV-2," 2022, Emerging Microbes & Infections
  • "High Neutralizing Antibody Levels Against Severe Acute Respiratory Syndrome Coronavirus 2 Omicron BA.1 and BA.2 After UB-612 Vaccine Booster," 2022, The Journal of Infectious Diseases

Throughout their career, Monath has produced a significant volume of work in infectious diseases, with a total of 87 publications in medicine-related fields. They have received recognition as a Fellow of the American Society of Tropical Medicine and Hygiene (ASTMH) in 2011.

Best Publications

  • Dengue: the risk to developed and developing countries

    Thomas P. Monath

  • ICTV Virus Taxonomy Profile: Flaviviridae.

    Peter Simmonds;Paul Becher;Jens Bukh;Ernest A. Gould

  • Epidemic arboviral diseases: priorities for research and public health

    Annelies Wilder-Smith;Annelies Wilder-Smith;Duane J Gubler;Scott C Weaver;Thomas P Monath

  • Immunization of Mice with Urease Vaccine Affords Protection against Helicobacter pylori Infection in the Absence of Antibodies and Is Mediated by MHC Class II–restricted Responses

    Thomas H. Ermak;Paul J. Giannasca;Richard Nichols;Gwendolyn A. Myers

  • Oral immunization with urease and Escherichia coli heat-labile enterotoxin is safe and immunogenic in Helicobacter pylori-infected adults.

    Pierre Michetti;Christianna Kreiss;Karen L. Kotloff;Nadine Porta

  • Persistence of neutralizing antibody 30-35 years after immunization with 17D yellow fever vaccine

    J D Poland;C H Calisher;T P Monath;W G Downs

  • Lassa Virus Isolation from Mastomys natalensis Rodents during an Epidemic in Sierra Leone

    Thomas P. Monath;Verne F. Newhouse;Graham E. Kemp;Henry W. Setzer

  • Recombinant chimeric yellow fever-dengue type 2 virus is immunogenic and protective in nonhuman primates.

    F. Guirakhoo;R. Weltzin;T. J. Chambers;Z.-X. Zhang

  • Safety and Efficacy of Chimeric Yellow Fever-Dengue Virus Tetravalent Vaccine Formulations in Nonhuman Primates

    F. Guirakhoo;K. Pugachev;Z. Zhang;G. Myers

  • Construction, Safety, and Immunogenicity in Nonhuman Primates of a Chimeric Yellow Fever-Dengue Virus Tetravalent Vaccine

    F. Guirakhoo;J. Arroyo;K. V. Pugachev;C. Miller

  • Oral Immunization with Recombinant Helicobacter pylori Urease Induces Secretory IgA Antibodies and Protects Mice from Challenge with Helicobacter felis

    Lee Ck;Weltzin R;Thomas Wd;Kleanthous H

  • Clostridium difficile toxoid vaccine in recurrent C. difficile-associated diarrhea

    Stavros Sougioultzis;Lorraine Kyne;Denise Drudy;Sarah Keates

  • The revised global yellow fever risk map and recommendations for vaccination, 2010: consensus of the Informal WHO Working Group on Geographic Risk for Yellow Fever.

    Emily S Jentes;Gilles Poumerol;Mark D Gershman;David R Hill

  • Proposed revision to the taxonomy of the genus Pestivirus, family Flaviviridae.

    Donald B. Smith;Donald B. Smith;Gregor Meyers;Jens Bukh;Ernest A. Gould

  • Chimeric live, attenuated vaccine against Japanese encephalitis (ChimeriVax-JE): phase 2 clinical trials for safety and immunogenicity, effect of vaccine dose and schedule, and memory response to challenge with inactivated Japanese encephalitis antigen.

    Thomas P. Monath;Farshad Guirakhoo;Richard Nichols;Sutee Yoksan

  • Clinical proof of principle for ChimeriVax™: recombinant live, attenuated vaccines against flavivirus infections

    Thomas P Monath;Karen McCarthy;Philip Bedford;Casey T Johnson

  • Protection against yellow fever in monkeys by immunization with yellow fever virus nonstructural protein NS1.

    J J Schlesinger;M W Brandriss;C B Cropp;T P Monath

  • ChimeriVax-West Nile Virus Live-Attenuated Vaccine: Preclinical Evaluation of Safety, Immunogenicity, and Efficacy

    Juan Arroyo;Chuck Miller;John Catalan;Gwendolyn A. Myers

  • Live attenuated chimeric yellow fever dengue type 2 (ChimeriVax-DEN2) vaccine: Phase I clinical trial for safety and immunogenicity: effect of yellow fever pre-immunity in induction of cross neutralizing antibody responses to all 4 dengue serotypes.

    Farshad Guirakhoo;Scott Kitchener;Dennis Morrison;Remi Forrat

  • A live, attenuated recombinant West Nile virus vaccine

    Thomas P. Monath;Jian Liu;Niranjan Kanesa-Thasan;Gwendolyn A. Myers

  • Immunogenicity, Genetic Stability, and Protective Efficacy of a Recombinant, Chimeric Yellow Fever-Japanese Encephalitis Virus (ChimeriVax-JE) as a Live, Attenuated Vaccine Candidate against Japanese Encephalitis☆

    F. Guirakhoo;Z.-X. Zhang;T.J. Chambers;S. Delagrave

  • Phase 2 Placebo-Controlled Trial of Two Vaccines to Prevent Ebola in Liberia

    Stephen B. Kennedy;Fatorma Bolay;Mark Kieh;Greg Grandits

  • Molecular basis for attenuation of neurovirulence of a yellow fever Virus/Japanese encephalitis virus chimera vaccine (ChimeriVax-JE).

    Juan Arroyo;Farshad Guirakhoo;Sabine Fenner;Zhen-Xi Zhang

  • Safety and immunogenicity of increasing doses of a Clostridium difficile toxoid vaccine administered to healthy adults.

    Karen L. Kotloff;Steven S. Wasserman;Genevieve A. Losonsky;William Thomas

Frequent Co-Authors

Dennis W. Trent
Dennis W. Trent The University of Texas Medical Branch at Galveston
Alan D.T. Barrett
Alan D.T. Barrett The University of Texas Medical Branch at Galveston
Richard J. Nichols
Richard J. Nichols University of Liverpool
Jean Lang
Jean Lang Sanofi (France)
Barry R. Miller
Barry R. Miller Centers for Disease Control and Prevention
Annelies Wilder-Smith
Annelies Wilder-Smith University of Bern
Sharon E. Frey
Sharon E. Frey Saint Louis University
Philip Bejon
Philip Bejon University of Oxford
John T. Roehrig
John T. Roehrig Centers for Disease Control and Prevention
J. Erin Staples
J. Erin Staples Centers for Disease Control and Prevention

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For those interested in Immunology, exploring related healthcare degrees can open diverse career opportunities. Accelerated nursing programs offer a fast track into clinical roles, with several options known for their accessibility. Students can consider the easiest absn programs to get into to quickly gain a Bachelor of Science in Nursing and begin working in patient care.

Licensed Practical Nurse (LPN) programs also provide a gateway into healthcare with programs that emphasize straightforward admission processes. Discovering easy admission lpn programs can help students start their nursing careers sooner with foundational skills in patient support and monitoring.

For advanced clinical roles, nurse practitioner degrees offer expanded responsibilities. Identifying which nurse practitioner program is easiest may assist applicants seeking programs that balance quality education with manageable admissions criteria.

Mental health is another critical area within immunology-related healthcare fields. Those interested can explore the top online pmhnp programs to find respected programs that offer strong clinical placement rates, crucial for hands-on experience in psychiatric mental health nursing.

Best Scientists Citing Thomas P. Monath

Trending Scientists

Recently Published Articles